Anglo-Swedish pharmaceutical group AstraZeneca's net profit drops by 56% in the third quarter to 1.18 billion euros ($1.53 billion) on expirations of some major US drug patents
Anglo-Swedish pharmaceutical group AstraZeneca's net profit fell 56% in the third quarter to 1.18 billion euros ($1.53 billion) on the expirations of some major US patents on drugs, including Seroquel and the Nexium by 2015 and Crestor by 2016. Revenue down 19% to $6.68 billion. in 2016. It is the first budget of the group under the leadership of the Frenchman Pascal Soriot [in the picture], the new CEO from Roche. In April, the American David Brennan resigned, having already announced the cut of 7,300 jobs by 2014.
October 25, 2012
